0.2666
price up icon2.46%   0.0064
pre-market  Pre-market:  .30   0.0334   +12.53%
loading
Adaptimmune Therapeutics Plc Adr stock is traded at $0.2666, with a volume of 432.07K. It is up +2.46% in the last 24 hours and down -3.68% over the past month. Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
See More
Previous Close:
$0.2602
Open:
$0.2598
24h Volume:
432.07K
Relative Volume:
0.27
Market Cap:
$62.81M
Revenue:
$175.04M
Net Income/Loss:
$-44.52M
P/E Ratio:
-1.4811
EPS:
-0.18
Net Cash Flow:
$-56.05M
1W Performance:
+11.92%
1M Performance:
-3.68%
6M Performance:
-64.45%
1Y Performance:
-75.31%
1-Day Range:
Value
$0.2598
$0.2717
1-Week Range:
Value
$0.2394
$0.2977
52-Week Range:
Value
$0.1951
$1.48

Adaptimmune Therapeutics Plc Adr Stock (ADAP) Company Profile

Name
Name
Adaptimmune Therapeutics Plc Adr
Name
Phone
44 1235 430000
Name
Address
60 JUBILEE AVENUE, ABINGDON, OXFORDSHIRE
Name
Employee
506
Name
Twitter
@Adaptimmune
Name
Next Earnings Date
2025-03-21
Name
Latest SEC Filings
Name
ADAP's Discussions on Twitter

Compare ADAP with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ADAP
Adaptimmune Therapeutics Plc Adr
0.2666 62.81M 175.04M -44.52M -56.05M -0.18
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.47 125.74B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
599.76 61.57B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
600.51 36.40B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
242.61 30.36B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
256.16 24.89B 3.81B -644.79M -669.77M -6.24

Adaptimmune Therapeutics Plc Adr Stock (ADAP) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-30-24 Initiated H.C. Wainwright Buy
May-30-24 Initiated Scotiabank Sector Outperform
Mar-24-23 Initiated Bryan Garnier Buy
Jan-03-23 Upgrade Guggenheim Neutral → Buy
Nov-09-22 Upgrade Mizuho Neutral → Buy
May-28-21 Initiated Barclays Underweight
Apr-22-20 Initiated Mizuho Neutral
Aug-02-19 Downgrade Guggenheim Buy → Neutral
May-31-19 Initiated ROTH Capital Buy
May-30-19 Resumed Citigroup Buy
May-07-19 Downgrade SVB Leerink Outperform → Mkt Perform
Mar-17-17 Initiated Wells Fargo Market Perform
Oct-24-16 Downgrade BofA/Merrill Neutral → Underperform
Sep-30-16 Initiated Raymond James Outperform
Feb-25-16 Initiated Citigroup Buy
Jun-01-15 Initiated BofA/Merrill Neutral
Jun-01-15 Initiated Guggenheim Buy
Jun-01-15 Initiated Leerink Partners Outperform
View All

Adaptimmune Therapeutics Plc Adr Stock (ADAP) Latest News

pulisher
Apr 24, 2025

The Adaptimmune Therapeutics Plc ADR (ADAP) had a good session last reading, didn’t it? - uspostnews.com

Apr 24, 2025
pulisher
Apr 24, 2025

How should investors view Lazard Inc (LAZ)? - uspostnews.com

Apr 24, 2025
pulisher
Apr 24, 2025

Olema Pharmaceuticals Inc (OLMA)’s results reveal risk - uspostnews.com

Apr 24, 2025
pulisher
Apr 24, 2025

It would be worthwhile to take a closer look at Quantum Corp (QMCO) - uspostnews.com

Apr 24, 2025
pulisher
Apr 24, 2025

Was there any good news for Neuronetics Inc (STIM) stock in the last session? - uspostnews.com

Apr 24, 2025
pulisher
Apr 02, 2025

Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Today’s Hot Stock - stocksregister.com

Apr 02, 2025
pulisher
Apr 01, 2025

H.C. Wainwright cuts Adaptimmune stock target to $3, maintains Buy By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

H.C. Wainwright cuts Adaptimmune stock target to $3, maintains Buy - Investing.com India

Apr 01, 2025
pulisher
Mar 26, 2025

Guggenheim cuts Adaptimmune target to $1.75, maintains Buy By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Guggenheim cuts Adaptimmune target to $1.75, maintains Buy - Investing.com

Mar 26, 2025
pulisher
Mar 25, 2025

Adaptimmune Therapeutics Amends Loan Agreement By Investing.com - Investing.com India

Mar 25, 2025
pulisher
Mar 24, 2025

Adaptimmune Therapeutics Amends Loan Agreement - Investing.com

Mar 24, 2025
pulisher
Mar 21, 2025

Scotiabank cuts Adaptimmune price target to $1.40, keeps rating By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

Scotiabank cuts Adaptimmune price target to $1.40, keeps rating - Investing.com

Mar 21, 2025
pulisher
Mar 20, 2025

Mizuho maintains Outperform on Adaptimmune, price target $1.50 By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

Mizuho maintains Outperform on Adaptimmune, price target $1.50 - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

Earnings call transcript: Adaptimmune Q4 2024 targets $25M sales in 2025 - Investing.com

Mar 20, 2025
pulisher
Mar 06, 2025

Adaptimmune Therapeutics PLC Sponsored ADR to Host Earnings Call - ACCESS Newswire

Mar 06, 2025
pulisher
Feb 25, 2025

LAG-3 Immunotherapies Market Set for Rapid Growth in the Coming 10 Years Across the 7MM as Next-Generation Therapies Advance | DelveInsight - GlobeNewswire Inc.

Feb 25, 2025
pulisher
Feb 25, 2025

Analysts Recommend Holding Your Position In Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) - Stocks Register

Feb 25, 2025
pulisher
Feb 19, 2025

Investing in Adaptimmune Therapeutics Plc ADR (ADAP) Is Getting More Attractive - Knox Daily

Feb 19, 2025
pulisher
Feb 12, 2025

Potential Price Increase for Coterra Energy Inc (CTRA) After Recent Insider Activity - Knox Daily

Feb 12, 2025
pulisher
Feb 12, 2025

Taking a Closer Look At Dollar Tree Inc (DLTR) Following Its Recent Trade - Knox Daily

Feb 12, 2025
pulisher
Feb 12, 2025

A Guide To The Risks Of Investing In Agilon Health Inc (AGL) - Knox Daily

Feb 12, 2025
pulisher
Feb 11, 2025

Daily Progress: Quanterix Corp (QTRX) Drop -3.57, Closing at 7.83 - The Dwinnex

Feb 11, 2025
pulisher
Feb 08, 2025

Following A 4.11% Weekly Incline, Is It Still A Buy For Amylyx Pharmaceuticals Inc (NASDAQ: AMLX)? - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 08, 2025

Should Outset Medical Inc (NASDAQ: OM) Rally After -544.44% Drop From High? - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 08, 2025

Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Stock Falling -5.24% Over A Month – Any Room For Its Value To Rise? – Marketing Sentinel - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 08, 2025

BioVie Inc (NASDAQ: BIVI): How Can A Stock Be Down -4.00% Year To Date, But Still Loser - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 07, 2025

Adaptimmune Therapeutics Plc ADR (ADAP) Stock: A Closer Look at the Moving Averages - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

SM Energy Co (SM): A Technical Analysis - The News Heater

Feb 07, 2025
pulisher
Feb 06, 2025

Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025 - Newsfile

Feb 06, 2025
pulisher
Feb 04, 2025

Adaptimmune Therapeutics Plc ADR (ADAP)’s stock price in review: A technical analysis - US Post News

Feb 04, 2025
pulisher
Feb 04, 2025

Quarterly Snapshot: Quick and Current Ratios for Adaptimmune Therapeutics Plc ADR (ADAP) - The Dwinnex

Feb 04, 2025
pulisher
Jan 17, 2025

Adaptimmune therapeutics COO sells shares worth $3,243 - Investing.com India

Jan 17, 2025
pulisher
Jan 17, 2025

Adaptimmune therapeutics' chief medical officer sells $3,243 in stock By Investing.com - Investing.com South Africa

Jan 17, 2025
pulisher
Jan 17, 2025

Adaptimmune therapeutics' chief medical officer sells $3,243 in stock - Investing.com India

Jan 17, 2025
pulisher
Jan 17, 2025

Adaptimmune therapeutics COO sells shares worth $3,243 By Investing.com - Investing.com South Africa

Jan 17, 2025
pulisher
Jan 16, 2025

Adaptimmune therapeutics COO William Bertrand sells $11,360 in shares - Investing.com India

Jan 16, 2025
pulisher
Jan 15, 2025

Adaptimmune therapeutics' chief medical officer sells $12,920 in shares - Investing.com

Jan 15, 2025
pulisher
Jan 15, 2025

Adaptimmune's chief commercial officer sells $7,467 in shares - Investing.com

Jan 15, 2025
pulisher
Jan 15, 2025

Adaptimmune therapeutics CEO Adrian Rawcliffe sells shares worth $34,639 - Investing.com

Jan 15, 2025
pulisher
Dec 23, 2024

AST SpaceMobile Inc Still Hasn’t Convinced Analysts? - Stocks Register

Dec 23, 2024
pulisher
Dec 23, 2024

These Numbers Show Just How Powerful Standard Lithium Ltd (AMEX: SLI) Stock ‎Is - Stocks Register

Dec 23, 2024
pulisher
Dec 23, 2024

What Did We Note About Insider Trading At Lithium Americas Corp (NewCo) (NYSE: LAC)? - Stocks Register

Dec 23, 2024
pulisher
Dec 23, 2024

Workhorse Group Inc (NASDAQ: WKHS) Could Pass $3.5 In One Year Stock Forecast - Stocks Register

Dec 23, 2024
pulisher
Dec 23, 2024

Barnes & Noble Education Inc (NYSE: BNED) -10.53% Decline Turns Investors Away - Stocks Register

Dec 23, 2024
pulisher
Dec 23, 2024

Applied Digital Corporation (NASDAQ: APLD) Could Pass $10 In One Year Stock Forecast - Stocks Register

Dec 23, 2024
pulisher
Dec 23, 2024

Asana Inc (NYSE: ASAN) Up 15.57% This Year: What Is Going To Happen Next - Stocks Register

Dec 23, 2024
pulisher
Dec 16, 2024

Adaptimmune's SWOT analysis: TCR-T pioneer faces challenges in stock outlook - Investing.com

Dec 16, 2024
pulisher
Dec 04, 2024

Adaptimmune's SWOT analysis: TCR-T therapy pioneer faces challenges post-FDA nod - Investing.com

Dec 04, 2024

Adaptimmune Therapeutics Plc Adr Stock (ADAP) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.54
price up icon 2.04%
$68.96
price down icon 2.60%
$32.03
price up icon 1.07%
$36.70
price up icon 10.44%
$120.54
price up icon 4.97%
biotechnology ONC
$256.16
price up icon 2.82%
Cap:     |  Volume (24h):